



PROF. MD. HAKAN BOZCUK

BRANCHE: Medical Oncology

BIRTH DATE: 1966

CONTACT INFORMATION: hakan.bozcuk@medicalpark.com.tr - 0 554 871 09 04/ 0 505 672 80 38

SCHOOLS OF GRADUATION:

St Bartholomew's Hospital – Medical Oncology – Research Expert (1997-1998)

Norfolk & Norwich Hospital, Medical Oncology- Specialist (1998-1999)

Addenbrooke's Hospital, Medical Oncology– Guest Specialist (1999-1999)

Akdeniz University, Medical Faculty – Specialist (1999-2000)

Akdeniz University, Medical Faculty – Assistant Professor (2000-2002)

Akdeniz University, Medical Faculty – Associate Professor (2002-2009)

Akdeniz University, Medical Faculty – Professor (2009)

MEDICAL INTERESTS:

Medical Oncology

BUSINESS EXPERIENCES:

Akdeniz University, Medical Faculty (1991-2014)

Medical Park Antalya Hospital Complex (2014-Halen)

PUBLICATIONS:

1. Ersoy F.F., Karayalcin U., Karayalcin B., Sapan M., Suleymanlar G., **Bozcuk H.**, Yakupoglu G. Transfer of Native Insulin through the Peritoneal Membrane during CAPD in Diabetic and Non-Diabetic Patients. *Abstracts of the 15th Annual CAPD Conference*, 1995; 15:1.
2. Sapan M., **Bozcuk H.**, Akbulut M., et al. Peritoneal Equilibration Test (PET) in CAPD patients. *Kidney Int* 48: (5), 1681-1681, 1995.
3. Aslan M., Yucel G., **Bozcuk H.**, Savas B. The effect of recombinant human granulocyte/macrophage-colony-stimulating factor (rHu GM-CSF) and rHu G-CSF administration on neutrophil chemiluminescence assay in patients following cyclic chemotherapy. *Free Radical Bio Med* 25:115-115, Suppl. 1, 1998.
4. **Bozcuk H.**, Turner B., Chan O., Reznick R., Ravi R., Hendry W. F., Oliver R.T.D. The response on CT 21 days after chemotherapy as a predictor of the need for surgery in germ cell cancer. *The Brit J Urol*, Vol.81, (Suppl. 3), 1998; 5.
5. Ustun H., Ersoy F.F., **Bozcuk H.**, Akca S., Sezer T., Suleymanlar G., Yakupoglu G. The effect of Cefodizime on peritoneal neutrophil and monocyte chemotaxis in CAPD patients. *Abstracts of the 18th Annual CAPD Conference*, 1998; 18: 1.
6. Mulatero C. W., **Bozcuk H.**, Oliver R.T.D., Mair G., Nargund V. Bladder sparing with synchronous combination chemo/radiotherapy in invasive bladder cancer. *Ann Oncol* 9:62-62, Suppl.4, 1998.
7. Turner BP., Sohaib SA., Hanson J., **Bozcuk H.**, Oliver R.T.D., Reznick R.H. Is 3D measurement of tumour volume valid, accurate and helpful technique in assessing response to chemotherapy? *European Radiology* 1999; 9:supplement 1, abst 955.
8. Owen N.J., Tsetis D., **Bozcuk H.**, Oliver R.T.D., Reznick R.H. Day 21 Computerised Tomography Scan Response as a Predictor of Need for Post Chemotherapy Surgery in Nonseminomatous Germ Cell Tumour. *Radiology* 213 P: 306-306, 1999.
9. **Bozcuk H.**, Uslu G., Karaveli S., Samur M, Ozdogan M, Savas B. Predictors of distant metastasis at presentation in breast cancer: A retrospective study also evaluating associations among common biological indicators. *Ann Oncol* 11:37-37, Suppl.4, 2000.
10. **Bozcuk H.**, Martin C. Does treatment delay affect survival in Non- Small Cell Lung Cancer? *ESTRO* 2000
11. **Bozcuk H.**, Martin WMC. Does treatment delay affect survival in Non- Small Cell Lung Cancer? A retrospective analysis of delay and other factors. *Brit J Cancer* 83:43-43, Suppl. 1, 2000.
12. **Bozcuk H.**, Samur M, Ozdogan M, Yildiz M, Savas B. Determinants of quality of life in a group of cancer patients in Turkey. *MASCC* 2001.
13. Kurtoglu AU, Yücel G, Ataman F, **Bozcuk H.** The respiratory burst activity of neutrophils in patients of lung cancer treated by radiotherapy. *Free Radical Bio Med* 33: 75 Suppl. 1, 2002.

14. **Bozcuk H**, Samur M, Koyuncu E, Yildiz M, Özdoğan M, Savaş B. A prediction model for the risk of intrahospital death in cancer patients: does it really work? *Proc Am Soc Clin Oncol*, Vol 21(1): 379-379, 2002.
15. Yalçın B, Üner A, Akbulut H, İçli F, Işıkdogan A, Büyükçelik A, Dinçol D, Demirkazık A, **Bozcuk H**. A new schedule of Mitomycin-C and Vinorelbine combination in patients with metastatic breast cancer resistant to anthracyclines and taxanes: A phase II study. *Ann Oncol* 13: 68-68, Suppl 5, 2002.
16. Savaş B, Tanyel E, **Bozcuk H**, Yeşilipek A, Karadoğan İ, Küpesiz A, Kurdoğlu E, Ündar L. Using MTT in vitro drug sensitivity test for the prediction of chemotherapy failure of leukemia patients. *Ann Oncol* 13:17-17, Suppl 5, 2002.
17. Ataman F, Uğur A, Yücel G, **Bozcuk H**, Şimşir V. Effect of fractionated regional external beam radiotherapy on neutrophil subpopulations (in peripheral blood count) of cancer patients. *Radiotherapy and Oncology* 64:200-200, Suppl 1, 2002.
18. **Bozcuk H**, Uslu G, Akan I, Samur M, Ozdogan M, Yildiz M, Artac M, Ozben T, Savas B. The association of chemotherapy response in metastatic breast cancer with growth factor pathways. *Proc Am Soc Clin Oncol*, Vol 22: A 149, 37-37, 2003.
19. Samur M, **Bozcuk H**, Ozdogan M, Yildiz M, Artac M, Savas B. What influences weight gain during adjuvant chemotherapy in women with breast cancer? *Proc Am Soc Clin Oncol*, Vol 22: A 292, 73-73, 2003.
20. Savas B, **Bozcuk H**, Ozdogan M, Karaveli F, Pe E, Artaç M, Aykut A, Samur M. Molecular and clinical parameters which determine the docetaxel response in metastatic breast cancer. *Proc Am Soc Clin Oncol*, Vol 23: A 9732, 888-888, 2004.
21. **Bozcuk H**, Dalmış B, Samur M, Savas B, Ozdogan M, Artac M, Yildiz M. Are baseline performance status and line of chemotherapy administration important for palliation of metastatic non-small cell lung cancer (NSCLC) with chemotherapy? *Proc Am Soc Clin Oncol*, Vol 23: A 8175, 768-768, 2004.
22. **Bozcuk H**, Gumus A, Ozbilim G, Sarper A, Ozdogan M, Artac M, Samur M, Savas B. Recursive partitioning analysis of selected molecular markers to predict mediastinal lymph node involvement in operable NSCLC. *Proc Am Soc Clin Oncol*, A 7320, 2005.
23. Aksu G, **Bozcuk H**, Korcum A, Sen CA. Does radiotherapy technique influence survival in rectal cancer? A multivariate analysis. *Eur J Cancer supplements*, A 704, 2005.
24. Ozdogan M, Samur M, Artac M, Yildiz M, Savas B, **Bozcuk H**. Factors effecting the disclosure practice of physicians treating cancer patients in Turkey.. *Eur J Cancer supplements*, A 1331, 2005.
25. Artac M, Pehlivan S, Akcan S, Pehlivan M, Gelen T, Itirli G, Aksoy NH, Ozdogan M, Savas B, **Bozcuk H**. The value of pharmacogenomic analysis of microsatellite instability (MSI) and XPD, XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma. *Proc Am Soc Clin Oncol*, A 13011, 2006.
26. **Bozcuk H**, Artac M, Akcan S, Korgun DK, Ozben T, Ozdogan M, Samur M, Mutlu H, Kargi A, Savas B. Does serum VEGF predict prognosis in metastatic colorectal carcinoma patients treated with XELIRI? *Proc Am Soc Clin Oncol*, A 13548, 2006.
27. Artac M, **Bozcuk H**, Afacan B, Ozdogan M, Timur M, Yildiz M, Samur M, Savas B. Metronomic cyclophosphamide – etoposide chemotherapy and serum VEGF level in metastatic breast cancer patients. *Ann Oncol* 17: 86-86, Suppl 9, 2006.
28. Artac M, Samur M, **Bozcuk H**, Afacan B, Ozdogan M. The impact of waist to hip ratio on survival in metastatic breast cancer patients treated with aromatase inhibitors. *Proc Am Soc Clin Oncol*, A 1070, 2007.
29. **Bozcuk HS**, Ozdogan M, Artac M, Yildiz M. Correlates of benefit from induction chemotherapy before radiotherapy in non-small cell lung cancer (NSCLC): a meta-

- analytical approach with meta-regression analysis. *Proc Am Soc Clin Oncol*, A 7575, 2008.
30. **Bozcuk H**, Yildiz M, Ozdogan M, Coskun HS, Kargı A, Mutlu H, Uysal M, Savas B. Determinants of health service satisfaction among cancer patients and their caregivers in oncology services: a survey study from two teaching hospitals in Turkey. *Eur J Cancer supplements*, A 3613, 2009
 31. Ozdogan M, **Bozcuk H**, Ozcan K, Tekeli A, Coskun HS, Kara A, Mutlu H, Kargı A, Uysal M, Savas B. The cancer education nursing unit's impact on informational needs of cancer patients-the first Turkish report. *Eur J Cancer supplements*, A 4242, 2009.
 32. **Bozcuk H**, Mutlu H, Artac M, Ozdogan M, Coskun HS, Kargı A, Uysal M, Savas B. An encouraging chemotherapy regimen in progressive small cell lung cancer. *Eur J Cancer supplements*, A 9130, 2009
 33. Ozdogan M, Kargı A, Artac M, **Bozcuk H**, Boruban MC, Coskun HS, Mutlu H, Eren OO, Uysal M, Savas B. Maintenance semi-metronomic oral cyclophosphamide and oral etoposide regimen in extensive stage small-cell lung cancer patients after responding to first line treatment. *Eur J Cancer supplements*, A 9131, 2009.
 34. Artac M, **Bozcuk H**, Kıyıcı A, Eren OO, Boruban MC, Ozdogan M. Correlation of serum leptin level and waist-to-hip ratio with overall survival of patients with metastatic breast cancer treated with aromatase inhibitors. *Proc Am Soc Clin Oncol*, A 1106, 2010.
 35. **Bozcuk H**, Yildiz M, Ozdogan M, Coskun HS, Kaya C, Cakal S, Mutlu A, Ulukal E, Ay S, Kilickaya P. The associates of the risk of febrile neutropenia after conventional dose chemotherapy in patients with common cancers. A prospective study from two tertiary cancer centers, *Eur J Cancer supplements*, A 3015, 2011.
 36. Artac M, Askin D, Kıyıcı A, Eren OO, Oncel M, Boruban MC, **Bozcuk H**. Does obesity change the effect of aromatase inhibitors (AIs) on estradiol, leptin, insulin, and IGF-1 serum levels in breast cancer patients? *J Clin Oncol* 30, 2012 (suppl; abstr e11008)
 37. Uysal M, **Bozcuk H**, Goksu SS, Tatli AM, Arslan D, Gunduz S, Coskun HS, Ozdogan M, Savas B. Proteinuria as a predictive factor in metastatic colorectal cancer patients treated with bevacizumab. *J Clin Oncol* 30, 2012 (suppl; abstr e14070)